DK2828292T3 - Jcv-neutraliserende antistoffer - Google Patents
Jcv-neutraliserende antistofferInfo
- Publication number
- DK2828292T3 DK2828292T3 DK13763643.7T DK13763643T DK2828292T3 DK 2828292 T3 DK2828292 T3 DK 2828292T3 DK 13763643 T DK13763643 T DK 13763643T DK 2828292 T3 DK2828292 T3 DK 2828292T3
- Authority
- DK
- Denmark
- Prior art keywords
- jcv
- neutralizing antibodies
- neutralizing
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613249P | 2012-03-20 | 2012-03-20 | |
| PCT/US2013/031853 WO2013142300A2 (en) | 2012-03-20 | 2013-03-15 | Jcv neutralizing antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2828292T3 true DK2828292T3 (da) | 2019-01-02 |
Family
ID=49223445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13763643.7T DK2828292T3 (da) | 2012-03-20 | 2013-03-15 | Jcv-neutraliserende antistoffer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9567391B2 (da) |
| EP (1) | EP2828292B1 (da) |
| CA (1) | CA2867910C (da) |
| DK (1) | DK2828292T3 (da) |
| ES (1) | ES2706173T3 (da) |
| WO (1) | WO2013142300A2 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2828284T3 (da) | 2012-03-20 | 2019-06-11 | Biogen Ma Inc | Jcv-neutraliserende antistoffer |
| ITTO20120570A1 (it) * | 2012-06-27 | 2013-12-28 | Pomona Ricerca Srl | Anticorpo monoclonale diretto contro il virus jc |
| CN104936980B (zh) | 2012-12-31 | 2019-06-07 | 生物控股有限公司 | 用于治疗和预防多瘤病毒相关的疾病的重组人抗体 |
| WO2015095770A1 (en) * | 2013-12-20 | 2015-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic jc polyomavirus compositions and methods of use |
| US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| CA3083363A1 (en) * | 2017-12-01 | 2019-06-06 | Novartis Ag | Polyomavirus neutralizing antibodies |
| WO2020119793A1 (en) * | 2018-12-14 | 2020-06-18 | Wuxi Biologics (Shanghai) Co., Ltd. | Humanized antibodies against ox40, method for preparing the same, and use thereof |
| US12410238B2 (en) | 2019-06-19 | 2025-09-09 | Icahn School Of Medicine At Mount Sinai | Monoclonal antibodies against JC virus |
| KR20230004725A (ko) * | 2020-04-22 | 2023-01-06 | 아케소 바이오파마, 인크. | 항-cd73 항체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2322560B1 (en) | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| HUE039865T2 (hu) * | 2005-12-20 | 2019-02-28 | Sbi Biotech Co Ltd | Anti-ILT7 antitest |
| US7655417B2 (en) | 2006-05-31 | 2010-02-02 | Hanwha Chemical Corporation | VCAM-1 specific monoclonal antibody |
| US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
| SI2308514T1 (sl) | 2007-03-23 | 2013-09-30 | To-Bbb Holding B.V. | Konjugati za prenos zdravila preko krvno-moĹľganske pregrade |
| CN101990439A (zh) * | 2007-07-06 | 2011-03-23 | 特鲁比昂药品公司 | 具有置于c末端的特异性结合结构域的结合肽 |
| ES2687259T5 (es) | 2008-06-25 | 2022-10-14 | Novartis Ag | Anticuerpos estables y solubles que inhiben TNF |
| WO2010090757A1 (en) * | 2009-02-05 | 2010-08-12 | Biogen Idec Ma Inc. | Methods for the detection of jc polyoma virus |
| WO2010129959A1 (en) | 2009-05-08 | 2010-11-11 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the prevention and treatment of lupus nephritis using anti-dsdna germline antibodies |
| EP2316481A1 (en) | 2009-10-30 | 2011-05-04 | Biomay Ag | Pharmaceutical composition for the treatment and prevention of a rhinovirus infection |
| DK2828284T3 (da) | 2012-03-20 | 2019-06-11 | Biogen Ma Inc | Jcv-neutraliserende antistoffer |
-
2013
- 2013-03-15 DK DK13763643.7T patent/DK2828292T3/da active
- 2013-03-15 US US14/386,228 patent/US9567391B2/en active Active
- 2013-03-15 CA CA2867910A patent/CA2867910C/en active Active
- 2013-03-15 ES ES13763643T patent/ES2706173T3/es active Active
- 2013-03-15 WO PCT/US2013/031853 patent/WO2013142300A2/en not_active Ceased
- 2013-03-15 EP EP13763643.7A patent/EP2828292B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2828292A2 (en) | 2015-01-28 |
| ES2706173T3 (es) | 2019-03-27 |
| WO2013142300A3 (en) | 2013-11-14 |
| EP2828292A4 (en) | 2016-03-30 |
| WO2013142300A2 (en) | 2013-09-26 |
| CA2867910A1 (en) | 2013-09-26 |
| CA2867910C (en) | 2023-09-26 |
| US9567391B2 (en) | 2017-02-14 |
| EP2828292B1 (en) | 2018-10-31 |
| US20150056188A1 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2024011I1 (el) | Αντισωματα anti-fcrn | |
| HUS2300021I1 (hu) | Anti-IL-36R antitestek | |
| DK2934584T3 (da) | Anti-gdf15-antistoffer | |
| HRP20181646T1 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
| EP2930240A4 (en) | ANTI-FOLR1 ANTIBODY | |
| DK2859055T3 (da) | Polymercoatings | |
| DK2825087T3 (da) | Otoscanner | |
| BR112014025037A2 (pt) | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente | |
| DK2839013T3 (da) | Ikke-disruptiv-gen-targetering | |
| DK2873977T3 (da) | Dobbeltdækker-rørdispenser | |
| DE112012006109A5 (de) | Okklusionsschienenanordnung | |
| DK2854722T3 (da) | Stomipose | |
| ME03751B (me) | Antitela usmerena na beta-amiloid | |
| HRP20181874T1 (hr) | Anti-cxcr3 protutijela | |
| DK2825157T3 (da) | Aminosyrelipider | |
| DK3431504T3 (da) | Antiphospholipase d4-antistof | |
| DK3521315T3 (da) | Anti-transglutaminase-2-antistoffer | |
| DK2931748T3 (da) | Bmp-6-antistoffer | |
| DK2935330T3 (da) | Anti-notch3-antistoffer | |
| DE112012006214T8 (de) | Wulstringwickler | |
| DK2831122T3 (da) | Anthocyanidin-kompleks | |
| CO6841994A2 (es) | Anticuerpos | |
| DE112012005566T8 (de) | Seltenerdnanoverbundmagnet | |
| DK2885638T3 (da) | Molekylenet | |
| DK2858657T3 (da) | Feijoafrugtekstrakt |